These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24709886)

  • 1. Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment.
    Ng YK; Lee JY; Supko KM; Khan A; Torres SM; Berwick M; Ho J; Kirkwood JM; Siegfried JM; Stabile LP
    Melanoma Res; 2014 Jun; 24(3):207-18. PubMed ID: 24709886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
    Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
    Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J
    PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
    Girotti MR; Pedersen M; Sanchez-Laorden B; Viros A; Turajlic S; Niculescu-Duvaz D; Zambon A; Sinclair J; Hayes A; Gore M; Lorigan P; Springer C; Larkin J; Jorgensen C; Marais R
    Cancer Discov; 2013 Feb; 3(2):158-67. PubMed ID: 23242808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma.
    Walter L; Heinzerling L
    Anticancer Res; 2018 Mar; 38(3):1335-1341. PubMed ID: 29491057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
    Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R
    Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.
    Spender LC; Ferguson GJ; Liu S; Cui C; Girotti MR; Sibbet G; Higgs EB; Shuttleworth MK; Hamilton T; Lorigan P; Weller M; Vincent DF; Sansom OJ; Frame M; Dijke PT; Marais R; Inman GJ
    Oncotarget; 2016 Dec; 7(50):81995-82012. PubMed ID: 27835901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
    Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
    Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.
    Carroll MJ; Parent CR; Page D; Kreeger PK
    BMC Cancer; 2019 Oct; 19(1):1025. PubMed ID: 31672130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma.
    Capparelli C; Rosenbaum S; Berger AC; Aplin AE
    J Biol Chem; 2015 Oct; 290(40):24267-77. PubMed ID: 26269601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.
    Nakamura Y; Hattori N; Iida N; Yamashita S; Mori A; Kimura K; Yoshino T; Ushijima T
    Cancer Lett; 2017 Aug; 402():100-109. PubMed ID: 28576751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
    Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
    Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
    Basile KJ; Le K; Hartsough EJ; Aplin AE
    Pigment Cell Melanoma Res; 2014 May; 27(3):479-84. PubMed ID: 24422853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAF
    Al-Wahaibi LH; Gouda AM; Abou-Ghadir OF; Salem OIA; Ali AT; Farghaly HS; Abdelrahman MH; Trembleau L; Abdu-Allah HHM; Youssif BGM
    Bioorg Chem; 2020 Nov; 104():104260. PubMed ID: 32920363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rescue of cell cycle progression in BRAF
    Toress-Collado AX; Nazarian R; Jazirehi AR
    Tumour Biol; 2017 Sep; 39(9):1010428317721620. PubMed ID: 28936920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.
    Paoluzzi L; Hanniford D; Sokolova E; Osman I; Darvishian F; Wang J; Bradner JE; Hernando E
    Cancer Med; 2016 Jun; 5(6):1183-93. PubMed ID: 27169980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
    Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
    Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A
    PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
    Tap WD; Gong KW; Dering J; Tseng Y; Ginther C; Pauletti G; Glaspy JA; Essner R; Bollag G; Hirth P; Zhang C; Slamon DJ
    Neoplasia; 2010 Aug; 12(8):637-49. PubMed ID: 20689758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.